Evidence map›Paper›PMID 32274326›Full record

ArticleJournal of bone oncology2020

Corrigendum to: ``The immune landscape of chondrosarcoma reveals an immunosuppressive environment in the dedifferentiated subtypes and exposes CSFR1+ macrophages as a promising therapeutic target.'' J Bone Oncol. 2020 Feb; 20: 100271.

Iseulys Richert, Anne Gomez-Brouchet, Corinne Bouvier, Gonzague Du Bouexic De Pinieux, Arie KaranianM, Jean-Yves Blay, Aurélie Dutour

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of bone oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Therapeutic Targets and Emerging Treatments in Advanced Chondrosarcoma.International journal of molecular sciences · 2022
    Review
  6. Review
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Iseulys RichertCRCL, Cell death and pediatric cancers team, U1052, UMR5286 Lyon, France.
Anne Gomez-BrouchetDepartment of Pathology, IUCT-Oncopole, CHU of Toulouse, Université de Toulouse 3. UMR1037 INSERM-Université Toulouse 3-ERL5294 CNRS, Toulouse, France.
Corinne BouvierDepartment of pathology, APHM La Timone, Aix Marseille University, MMG, France.
Gonzague Du Bouexic De PinieuxDepartment of pathology, Centre Hospitalier Universitaire Tours, 37000 Tours, France.
Arie KaranianMDepartment of pathology, Centre Léon Bérard, Lyon, France.
Jean-Yves BlayCRCL, Cell death and pediatric cancers team, U1052, UMR5286 Lyon, France.
Aurélie DutourCRCL, Cell death and pediatric cancers team, U1052, UMR5286 Lyon, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.1016/j.jbo.2019.100271.].

Identifiers

PMID32274326
PMCPMC7132089

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.